Coexisting autoimmune diseases that could interfere with the attribution of disease activity or pose an increased safety risk
Participants with the following cardiac conditions are excluded:
1. History of heart failure New York Heart Association (NYHA) class III or IV;
2. History of myocardial infarction, cardiovascular angioplasty or stenting, unstable angina, or other serious heart diseases within 12 months of enrollment.
History of severe central nervous system (CNS) disorders that could compromise the participant's ability to comply with protocol requirements or interfere with the accuracy of study assessments
Current or prior malignancy unless the malignancy was treated with curative intent and the subject has no known active malignant disease present for ≥ 5 years before enrollment
Primary immune deficiency
Presence of uncontrolled infections
History of untreated hepatitis C virus, or syphilis
History of HIV infection, or active or latent hepatitis B virus (HBV) infection.
Evidence of active Epstein-Barr virus (EBV), cytomegalovirus (CMV) or tuberculosis (TB)
History of prior CAR-T cell therapy or any other genetically modified immune cell therapy
Having received live/attenuated vaccine within 4 weeks prior to enrollment
Participants with a history of hypersensitivity to tacrolimus
Those who have participated in other interventional clinical trials within 30 days before enrollment
Participants who meet disease-specific exclusionary criteria as specified
